150 related articles for article (PubMed ID: 16725321)
1. Novel, potent, selective, and orally bioavailable human betaII-tryptase inhibitors.
Sperandio D; Tai VW; Lohman J; Hirschbein B; Mendonca R; Lee CS; Spencer JR; Janc J; Nguyen M; Beltman J; Sprengeler P; Scheerens H; Lin T; Liu L; Gadre A; Kellogg A; Green MJ; McGrath ME
Bioorg Med Chem Lett; 2006 Aug; 16(15):4085-9. PubMed ID: 16725321
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis, and biological activity of potent and selective inhibitors of mast cell tryptase.
Hopkins CR; Czekaj M; Kaye SS; Gao Z; Pribish J; Pauls H; Liang G; Sides K; Cramer D; Cairns J; Luo Y; Lim HK; Vaz R; Rebello S; Maignan S; Dupuy A; Mathieu M; Levell J
Bioorg Med Chem Lett; 2005 Jun; 15(11):2734-7. PubMed ID: 15911249
[TBL] [Abstract][Full Text] [Related]
3. Design and synthesis of selective keto-1,2,4-oxadiazole-based tryptase inhibitors.
Palmer JT; Rydzewski RM; Mendonca RV; Sperandio D; Spencer JR; Hirschbein BL; Lohman J; Beltman J; Nguyen M; Liu L
Bioorg Med Chem Lett; 2006 Jul; 16(13):3434-9. PubMed ID: 16644215
[TBL] [Abstract][Full Text] [Related]
4. Design of bivalent ligands using hydrogen bond linkers: synthesis and evaluation of inhibitors for human beta-tryptase.
Vaz RJ; Gao Z; Pribish J; Chen X; Levell J; Davis L; Albert E; Brollo M; Ugolini A; Cramer DM; Cairns J; Sides K; Liu F; Kwong J; Kang J; Rebello S; Elliot M; Lim H; Chellaraj V; Singleton RW; Li Y
Bioorg Med Chem Lett; 2004 Dec; 14(24):6053-6. PubMed ID: 15546728
[TBL] [Abstract][Full Text] [Related]
5. Design of novel, potent, and selective human beta-tryptase inhibitors based on alpha-keto-[1,2,4]-oxadiazoles.
Lee CS; Liu W; Sprengeler PA; Somoza JR; Janc JW; Sperandio D; Spencer JR; Green MJ; McGrath ME
Bioorg Med Chem Lett; 2006 Aug; 16(15):4036-40. PubMed ID: 16714109
[TBL] [Abstract][Full Text] [Related]
6. Novel pyrazinone inhibitors of mast cell tryptase: synthesis and SAR evaluation.
Hopkins C; Neuenschwander K; Scotese A; Jackson S; Nieduzak T; Pauls H; Liang G; Sides K; Cramer D; Cairns J; Maignan S; Mathieu M
Bioorg Med Chem Lett; 2004 Oct; 14(19):4819-23. PubMed ID: 15341931
[TBL] [Abstract][Full Text] [Related]
7. Solid-phase synthesis and SAR of 4-carboxy-2-azetidinone mechanism-based tryptase inhibitors.
Sutton JC; Bolton SA; Davis ME; Hartl KS; Jacobson B; Mathur A; Ogletree ML; Slusarchyk WA; Zahler R; Seiler SM; Bisacchi GS
Bioorg Med Chem Lett; 2004 May; 14(9):2233-9. PubMed ID: 15081015
[TBL] [Abstract][Full Text] [Related]
8. Synthesis of potent and highly selective nonguanidine azetidinone inhibitors of human tryptase.
Bisacchi GS; Slusarchyk WA; Bolton SA; Hartl KS; Jacobs G; Mathur A; Meng W; Ogletree ML; Pi Z; Sutton JC; Treuner U; Zahler R; Zhao G; Seiler SM
Bioorg Med Chem Lett; 2004 May; 14(9):2227-31. PubMed ID: 15081014
[TBL] [Abstract][Full Text] [Related]
9. 4-aminophenylalanine and 4-aminocyclohexylalanine derivatives as potent, selective, and orally bioavailable inhibitors of dipeptidyl peptidase IV.
Duffy JL; Kirk BA; Wang L; Eiermann GJ; He H; Leiting B; Lyons KA; Patel RA; Patel SB; Petrov A; Scapin G; Wu JK; Thornberry NA; Weber AE
Bioorg Med Chem Lett; 2007 May; 17(10):2879-85. PubMed ID: 17350841
[TBL] [Abstract][Full Text] [Related]
10. Structure based design of 4-(3-aminomethylphenyl)piperidinyl-1-amides: novel, potent, selective, and orally bioavailable inhibitors of betaII tryptase.
Levell J; Astles P; Eastwood P; Cairns J; Houille O; Aldous S; Merriman G; Whiteley B; Pribish J; Czekaj M; Liang G; Maignan S; Guilloteau JP; Dupuy A; Davidson J; Harrison T; Morley A; Watson S; Fenton G; McCarthy C; Romano J; Mathew R; Engers D; Gardyan M; Sides K; Kwong J; Tsay J; Rebello S; Shen L; Wang J; Luo Y; Giardino O; Lim HK; Smith K; Pauls H
Bioorg Med Chem; 2005 Apr; 13(8):2859-72. PubMed ID: 15781396
[TBL] [Abstract][Full Text] [Related]
11. Novel, potent and orally bioavailable indolizidinone-derived inhibitors of the hepatitis C virus NS3 protease.
Clarke MO; Byun D; Chen X; Doerffler E; Leavitt SA; Sheng XC; Yang CY; Kim CU
Bioorg Med Chem Lett; 2012 Jan; 22(2):1095-8. PubMed ID: 22189140
[TBL] [Abstract][Full Text] [Related]
12. Structure-based library design and the discovery of a potent and selective mast cell β-tryptase inhibitor as an oral therapeutic agent.
Liang G; Aldous S; Merriman G; Levell J; Pribish J; Cairns J; Chen X; Maignan S; Mathieu M; Tsay J; Sides K; Rebello S; Whitely B; Morize I; Pauls HW
Bioorg Med Chem Lett; 2012 Jan; 22(2):1049-54. PubMed ID: 22192588
[TBL] [Abstract][Full Text] [Related]
13. Discovery of potent, selective, and orally bioavailable oxadiazole-based dipeptidyl peptidase IV inhibitors.
Xu J; Wei L; Mathvink RJ; Edmondson SD; Eiermann GJ; He H; Leone JF; Leiting B; Lyons KA; Marsilio F; Patel RA; Patel SB; Petrov A; Scapin G; Wu JK; Thornberry NA; Weber AE
Bioorg Med Chem Lett; 2006 Oct; 16(20):5373-7. PubMed ID: 16919457
[TBL] [Abstract][Full Text] [Related]
14. Development of tryptase inhibitors derived from thalidomide.
Tetsuhashi M; Ishikawa M; Hashimoto M; Hashimoto Y; Aoyama H
Bioorg Med Chem; 2010 Jul; 18(14):5323-38. PubMed ID: 20561792
[TBL] [Abstract][Full Text] [Related]
15. Potent, selective, and orally bioavailable matrix metalloproteinase-13 inhibitors for the treatment of osteoarthritis.
Hu Y; Xiang JS; DiGrandi MJ; Du X; Ipek M; Laakso LM; Li J; Li W; Rush TS; Schmid J; Skotnicki JS; Tam S; Thomason JR; Wang Q; Levin JI
Bioorg Med Chem; 2005 Dec; 13(24):6629-44. PubMed ID: 16216515
[TBL] [Abstract][Full Text] [Related]
16. Dibasic inhibitors of human mast cell tryptase. Part 3: identification of a series of potent and selective inhibitors containing the benzamidine functionality.
Dener JM; Rice KD; Newcomb WS; Wang VR; Young WB; Gangloff AR; Kuo EY; Cregar L; Putnam D; Wong M
Bioorg Med Chem Lett; 2001 Jul; 11(13):1629-33. PubMed ID: 11425524
[TBL] [Abstract][Full Text] [Related]
17. Discovery of potent, selective and orally bioavailable triaryl-sulfonamide based PTP1B inhibitors.
Patel D; Jain M; Shah SR; Bahekar R; Jadav P; Joharapurkar A; Dhanesha N; Shaikh M; Sairam KV; Kapadnis P
Bioorg Med Chem Lett; 2012 Jan; 22(2):1111-7. PubMed ID: 22189136
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and evaluation of 4-substituted benzylamine derivatives as beta-tryptase inhibitors.
Miyazaki Y; Kato Y; Manabe T; Shimada H; Mizuno M; Egusa T; Ohkouchi M; Shiromizu I; Matsusue T; Yamamoto I
Bioorg Med Chem Lett; 2006 Jun; 16(11):2986-90. PubMed ID: 16540315
[TBL] [Abstract][Full Text] [Related]
19. Design and synthesis of potent, orally active, inhibitors of carboxypeptidase U (TAFIa).
Polla MO; Tottie L; Nordén C; Linschoten M; Müsil D; Trumpp-Kallmeyer S; Aukrust IR; Ringom R; Holm KH; Neset SM; Sandberg M; Thurmond J; Yu P; Hategan G; Anderson H
Bioorg Med Chem; 2004 Mar; 12(5):1151-75. PubMed ID: 14980627
[TBL] [Abstract][Full Text] [Related]
20. Potent, nonpeptide inhibitors of human mast cell tryptase. Synthesis and biological evaluation of novel spirocyclic piperidine amide derivatives.
Costanzo MJ; Yabut SC; Zhang HC; White KB; de Garavilla L; Wang Y; Minor LK; Tounge BA; Barnakov AN; Lewandowski F; Milligan C; Spurlino JC; Abraham WM; Boswell-Smith V; Page CP; Maryanoff BE
Bioorg Med Chem Lett; 2008 Mar; 18(6):2114-21. PubMed ID: 18272363
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
